Results 41 to 50 of about 519,309 (312)

Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot   +6 more
wiley   +1 more source

Pharmaceutical excipients - the continuing paradox(es) of formulation science [PDF]

open access: yes, 2016
One of the paradoxes of pharmaceutical formulation science is that, although excipients do not treat the disease, the disease cannot be treated without them.
R. Christian Moreton
core  

Dendrimer entrapped microsponge gel of dithranol for effective topical treatment

open access: yesHeliyon, 2019
Dithranol is one of the important topical agents for the treatment of psoriasis, a chronic inflammatory skin disease with aberrant differentiation of keratinocytes.
Pushpendra Kumar Tripathi   +4 more
doaj   +1 more source

Ironic Medications: A Narrative‐Based Psycho‐Educational Intervention to Explore Patient–Provider Communication in Adolescents With Haematological Cancer

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Adolescents with haematological malignancies face significant emotional and relational challenges, often accompanied by difficulties in communicating their needs within the healthcare context. To address these issues, a narrative‐based psycho‐educational intervention based on the creation and prescription of Ironic Medications was ...
Marta Stoppa   +7 more
wiley   +1 more source

Risk factors and prescription patterns analysis for macrolide-resistant Mycoplasma pneumoniae pneumonia in children

open access: yesiScience
Summary: First-line macrolide therapy is encountering challenges due to the escalating incidence of macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMPP).
Yun Lu   +4 more
doaj   +1 more source

Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model

open access: yesHeliyon, 2019
The present study aims at developing a new, ultrafine particle-based efficient antibiotic delivery system for the treatment of tuberculosis. The carrier material to make the rifampicin (RIF)-loaded particles is a low molecular weight star-shaped polymer ...
Jorge Ragusa   +5 more
doaj   +1 more source

Childhood Acute Lymphoblastic Leukemia Survival in Western Kenya: Reduction in Early Deaths and Treatment Abandonment

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background An earlier study on children diagnosed with acute lymphoblastic leukemia (ALL) at Moi Teaching and Referral Hospital (MTRH) in Kenya reported a low event‐free survival (EFS), excess treatment abandonment, and high induction mortality.
Gilbert Olbara   +7 more
wiley   +1 more source

Potential protective function of the sterol regulatory element binding factor 1–fatty acid desaturase 1/2 axis in early-stage age-related macular degeneration

open access: yesHeliyon, 2017
Age-related macular degeneration (AMD) is the most common cause of vision loss in elderly individuals throughout the developed world. Inhibitors of vascular endothelial growth factor have been successfully used to treat choroidal neovascularization in ...
Yoshifumi Ashikawa   +11 more
doaj   +1 more source

Avenanthramides as lipoxygenase inhibitors

open access: yesHeliyon, 2020
Avenanthramides (AVAs) present in oats are amides of anthranilic and cinnamic acids. AVAs are potent antioxidants and have anti-inflammatory properties.
Rikard Landberg   +2 more
doaj   +1 more source

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALL

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Adding blinatumomab to standard chemotherapy for infants with KMT2A‐rearranged acute B‐cell lymphoblastic leukemia (KMT2A‐r B‐ALL) improves outcomes. Although blinatumomab impairs immunoglobulin G (lgG) production, increasing infection susceptibility, IgG recovery remains poorly understood.
Miguel Vieira Martins   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy